Aug 23, 2019
The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...
Read More...
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper